Yaron Daniely, PhD, MBA, CEO of Alcobra Pharma talks about MDX, which, if approved, will be the first therapy of its kind for Fragile X Syndrome, the orphan disease that is closely related to autism. In studies, patients who took MDX  benefited cognitively, paving the way for a treatment to help this community’s unmet need. Alcobra has completed its enrollment of a Phase III study for adult ADHD, and expect to see results in Q3 of 2014. If successful in clinical trials, the drug would be available to the public as early as January of 2017.